21090 ⎘
Medicinal preparations containing antigens or antibodies; Bacterial antigens Mycobacterium, e.g. Mycobacterium tuberculosis
Multi-dose compositions containing an antimicrobial polyamide or octenidine preservative
#302Global gene regulators (GGR) as vaccine candidates against
#303LPS vaccine
#304Vaccine comprising beta-herpesvirus
#305COMPOSITIONS AND METHODS FOR STABILIZATION OF ACTIVE AGENTS
#306Multivalent vaccine for protection against mycobacterial infections and methods of using the same
#307proteins
#308MSP nanopores and related methods
#309VACCINE DELIVERY METHOD
#310Adjuvant for mucosal vaccine
#311Method for preventing or treating infection
#312Method and compositions
#313Synthetic glucopyranosyl lipid adjuvants
#314Composite antigenic sequences and vaccines
#315METHODS FOR THE TREATMENT OF BLADDER CANCER
#316Prevention and treatment of mycobacterium infection
#317Methods and compositions for transgene expression in a herpesvirus vector system
#318Method for the treatment of bladder cancer
#319Therapeutic cancer vaccine
#320Immunogenic composition for modulating the immune system and methods to treat bacterial infections in a subject
#321Methods for inducing an immune response
#322E2F4 SIGNATURE FOR USE IN DIAGNOSING AND TREATING BREAST AND BLADDER CANCER
#323Methods for inducing an immune response
#324Recombinant BCG expressing antigens of the ESX-1 secretion system
#325Treating bladder cancer patients and identifying bladder cancer patients responsive to treatment
#326Compositions and methods for immunodominant antigens
#327Parainfluenza virus 5 based vaccines
#328Compositions and methods
#329Method for preventing or treating infection
#330Vaccine candidates against johne's disease
#331Proteins expressed by and not by BCG and their use as diagnostic reagents and vaccines
#332M.tuberculosis vaccines
#333BIOINFORMATIC PROCESSES FOR DETERMINATION OF PEPTIDE BINDING
#334Methods and materials for producing immune responses against polypeptides involved in antibiotic resistance
#335Specific and unique T cell responses and molecular signatures for the treatment and diagnosis of
#336Methods for producing an immune response to tuberculosis
#337Checkpoint inhibitor and a whole cell for use in cancer therapy
#338Compositions and methods for immunodominant antigens of
#339Monoclonal antibodies that modulate immunity to MTB and enhance immune clearance
#340Polymer particles and uses thereof
#341Vaccine and therapeutic delivery system
#342Fusion of heterooligomeric mycobacterial antigens
#343MYCOBACTERIAL ANTIGEN COMPOSITION
#344Single vial vaccine formulations
#345Immunomodulatory compositions and methods of use thereof
#346Mycobacterial antigen composition
#347Methods of identifying subjects responsive to treatment for type 1 diabetes and compositions for treating the same
#348Vaccines with interleukin-33 as an adjuvant
#349A SINGLE OR MULTISTAGE MYCOBACTERIUM AVIUM SUBSP. PARATUBERCULOSIS SUBUNIT VACCINE
#350LPS VACCINE
#351COMPOUNDS AND METHODS FOR DIAGNOSIS AND IMMUNOTHERAPY OF TUBERCULOSIS
#352Mycobacterium Antigenic Composition
#353Biomarkers for (MAP)
#354Compositions and methods for the treatment or prevention of tuberculosis
#355Methods and kits for determining tuberculosis infection status
#356Mucosal vaccine composition
#357Compositions and methods
#358Recombinant as a vaccine
#359IMMUNOGENIC COMPOSITIONS AGAINST TUBERCULOSIS
#360POLYMER PARTICLES AND USES THEROF
#361Proteins expressed by and not by BCG and their use as diagnostic reagents and vaccines
#362Mycobacterium antigens
#363Proteins expressed by mycobacterium tuberculosis and not by BCG and their use as diagnostic reagents and vaccines
#364Bacterial Ribonucleic Acid Cell Wall Compositions and Methods of Making and Using Them
#365MSP nanopores and related methods
#366VACCINATION WITH RECOMBINANT MYCOBACTERIUM TUBERCULOSIS PknD ATTENUATES BACTERIAL DISSEMINATION TO THE BRAIN
#367Treatment of cancer with naltrexone
#368Phospholipid drug analogs
#369CANCER THERAPY
#370VACCINE COMPOSITION CONTAINING SYNTHETIC ADJUVANT
#371Vaccine and therapeutic delivery system
#372Anti-mycobacterial vaccines
#373Synthetic immunogens for prophylaxis or treatment of tuberculosis
#374Prevention and treatment of mycobacterium infection
#375Cytomegalovirus vectors enabling control of T cell targeting
#376Nanoparticle-based compositions
#377Methods of treating bladder cancer
#378Short oligonucleotides as vaccine adjuvants and therapeutic agents
#379USE OF REPLICATION DEFICIENT HSV-1 AS A VACCINE VECTOR FOR THE DELI VARY OF HIV-1 TAT ANTIGEN
#380Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
#381Vaccine composition containing synthetic adjuvant
#382PODXL in bladder cancer
#383Multivalent PCV2 immunogenic compositions and methods of producing such compositions
#384Multivalent PCV2 immunogenic compositions and methods of producing such compositions
#385Recombinant mycobacterium encoding a heparin-binding hemagglutinin (HBHA) fusion protein and uses thereof
#386vaccines
#387Method of treating desmocollin-3 expressing cancer with
#388Induction of antigen-specific tolerance by peripheral phagocytosis
#389Compositions comprising soluble HLA/M. tuberculosis-specific ligand complexes and methods of production and use thereof
#390Tuberculosis vaccine and method of using same
#391Immunoglobulin-binding human mycoplasma antigens and methods of use thereof
#392Treatment of post-traumatic stress disorder with isolated
#393MODIFIED BCG STRAINS WITH REDUCED OR ELIMINATED ACTIVITY OF LSR2 AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
#394Method for preventing or treating infection
#395USE OF MEMBRANE VESICLE-BASED VACCINE AGAINST M. TUBERCULOSIS
#396Bacterial ribonucleic acid cell wall compositions and methods of making and using them
#397Methods for producing an immune response to tuberculosis
#398PLASTID-EXPRESSED MYCOBACTERIUM TUBERCULOSIS VACCINE ANTIGENS ESAT-6 AND MTB72F FUSED TO CHOLERA TOXIN B SUBUNIT
#399COMPOSITIONS AND METHODS FOR TREATING AN ACTIVE MYCOBACTERIUM TUBERCULOSIS INFECTION
#400Inactivated mycobacteria for oral use in the prevention of tuberculosis
#401Compositions and methods for immunodominant antigens of
#402POLYSACCHARIDE COMPOSITIONS AND METHODS OF USE
#403Mycobacterial antigen vaccine
#404COMPOSITION FOR USE IN MYCOBACTERIA VACCINATION
#405METHOD FOR ATTENUATING A BACTERIUM OF THE MYCOBACTERIUM TUBERCULOSIS COMPLEX FOR PRODUCING A TUBERCULOSIS VACCINE
#406Recombinant strain of calmette-guerin (BCG), immunogenic composition and use
#407Methods and devices for tuberculosis diagnosis using biomarker profiles
#408Method for diagnosing tuberculosis disease by detecting induced markers after stimulation of T-cells with antigens
#409IMMUNOLOGICAL MARKERS FOR ADJUVANT THERAPY IN MELANOMA
#410ΔESX-3 mutants
#411MTB-C vaccine against asthma
#412Modified antigens
#413Tuberculosis TB vaccine to prevent reactivation
#414Modified coiled coil type proteins having improved properties
#415Cancer Treatment by Immunotherapy With BCG or Antigenically Related Non-Pathogenic Mycobacteria
#416Enhancing immunity to tuberculosis
#417Subunit vaccine delivery platform for robust humoral and cellular immune responses
#418Live recombinant booster vaccine against tuberculosis
#419Compositions And Methods For Immunodominant Antigens
#420RECOMBINANT BACTERIUM FOR INDUCTION OF CELLULAR IMMUNE RESPONSE
#421Liposome formulation suitable for treating or preventing tuberculosis
#422Bacterial vaccine
#423Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
#424Tuberculosis compositions and methods of using the same
#425PIV5 as oncolytic agent
#426Modified epitopes for boosting CD4+ T-cell responses
#427Immunogenic Treatment Of Cancer
#428METHODS AND MATERIALS FOR PRODUCING IMMUNE RESPONSES AGAINST POLYPEPTIDES INVOLVED IN ANTIBIOTIC RESISTANCE
#429Methods of using a vaccine composition containing synthetic adjuvant
#430IMMUNOMODULATOR FOR THE TREATMENT OF CANCEROUS TUMORS IN THE EPITHELIAL TISSUE LINING SURFACES INSIDE OR OUTSIDE BODY ORGANS
#431Bacterial ribonucleic acid cell wall compositions and methods of making and using them
#432Synthetic glucopyranosyl lipid adjuvants
#433ORF2 PROTEIN OF PCV2 SUBTYPE A (PCV2A) FOR USE IN CROSS-PROTECTION
#434THERAPEUTIC VACCINATION AGAINST ACTIVE TUBERCULOSIS
#435Vaccine candidates against Johne's disease
#436Compositions and methods
#437MSP nanopores and related methods
#438Msp nanopores and related methods
#439Therapeutic agent for infections, and treatment method using same
#440Mycobacterium antigens
#441COMPOSITIONS AND METHODS FOR STABILIZATION OF ACTIVE AGENTS
#442Global gene regulators (GGR) as vaccine candidates against paratuberculosis
#443Msp nanopores and related methods
#444Treatments for
#445Use of an IL12 receptor-beta 1 splice variant to diagnose active tuberculosis
#446Proteins expressed by mycobacterium tuberculosis and not by BCG and their use as diagnostic reagents and vaccines
#447RECOMBINANT BCG STRAINS WITH ENHANCED ABILITY TO INHIBIT INTRACELLULAR MYCOBACTERIAL GROWTH
#448Compositions and methods for inducing an immune response
#449MODIFIED CATIONIC LIPOSOME ADJUVANTS
#450VACCINE COMPOSITION CONTAINING SYNTHETIC ADJUVANT
#451Method of vaccination comprising a histone deacetylase inhibitor
#452Mutant pores
#453Methods and compositions for treating autoimmune diseases
#454Methods for pathogen detection and disease treatment
#455Compositions and methods
#456Bacterial ribonucleic acid cell wall compositions and methods of making and using them
#457VACCINES FOR PREVENTION AND TREATMENT OF TUBERCULOSIS
#458Exosomes and diagnostic biomarkers
#459Recombinant mycobacterium avium subsp. paratuberculosis proteins induce immunity and protect against infection
#460Vaccines with enhanced immune response and methods for their preparation
#461TUBERCULOSIS RV2386C PROTEIN, COMPOSITIONS AND USES THEREOF
#462Method for preventing or treating infection
#463Immunogenic composition for immune system modulation and use thereof, method for treating and preventing diseases, method for inducing cell regeneration and method for restoring immune response
#464Composition and Method for Enhancing an Immune Response
#465Vaccine composition containing synthetic adjuvant
#466Method for the production of protein complexes and vaccine compositions comprising the same
#467Antigens and epitopes derived from
#468Recombinant mycobacterium as a vaccine
#469Therapeutic Cancer Vaccine
#470Modulation of antigen immunogenicity by addition of epitopes recognized by NKT cells
#471antigenic composition
#472Determination of the efficacy of an anti-mycobacterial vaccination
#473Combination heptavalent vaccine
#474antigenic composition
#475Recombinant mycobacterium as vaccine for use in humans
#476Phospholipid drug analogs
#477Tuberculosis vaccine and method of using same
#478Vaccine for inducing an improved immune reaction
#479Method for Immunising a Subject against Mycobacterium Tuberculosis or Mycobacterium Bovis
#480Phospholipid drug analogs
#481Phospholipid drug analogs
#482Proteins expressed by mycobacterium tuberculosis and not by BCG and their use as diagnostic reagents and vaccines
#483EPITOPE THERAPY FOR INFECTIOUS DISEASES
#484Methods to increase transgene expression from bacterial-based delivery systems by co-expressing suppressors of the eukaryotic type I interferon response
#485Immunogenic compositions comprising polypeptides and fusions thereof
#486Immunogenic compositions against tuberculosis
#487Synthetic immunogen useful for generating long lasting immunity and protection against pathogens
#488Therapeutic vaccination against active Tuberculosis
#489CERAMIDE-LIKE GLYCOLIPID-ASSOCIATED BACTERIAL VACCINES AND USES THEREOF
#490IN VIVO TARGETING OF DENDRITIC CELLS
#491Bacterial ribonucleic acid cell wall compositions and methods of making and using them
#492Mycobacterial antigen composition
#493Diagnostic reagents
#494RECOMBINANT BCG STRAINS WITH ENHANCED ABILITY TO INHIBIT INTRACELLULAR MYCOBACTERIAL GROWTH
#495Method for the diagnosis of tuberculosis
#496ATTENUATED MYCOBACTERIAL STRAIN AS NOVEL VACCINE AGAINST TUBERCULOSIS
#497METHODS FOR PREVENTING OR TREATING A DISEASE OR CONDITION ASSOCIATED WITH MYCOBACTERIUM AVIUM SUBSPECIES PARATUBERCULOSIS
#498NOVEL LIVE RECOMBINANT BOOSTER VACCINE AGAINST TUBERCULOSIS
#499Methods for detecting a infection
#500Compositions and methods for immunodominant antigens of
#501Methods of using a vaccine composition containing synthetic adjuvant
#502COMPOUNDS AND METHODS FOR DIAGNOSIS AND IMMUNOTHERAPY OF TUBERCULOSIS
#503Tuberculosis vaccine
#504Recombinant baculovirus vaccine
#505Therapeutic Agent for infections, and treatment method using the same
#506ANTIGENIC COMPOSITIONS
#507OLIGOPEPTIDES AND THEIR USE FOR TREATING INFECTIOUS DISEASES
#508Modified tuberculosis antigens
#509Mycobacterial vaccines
#510Methods for detecting a mycobacterium tuberculosis infection
#511Pro-apoptotic bacterial vaccines to enhance cellular immune responses
#512Mycobacterium tuberculosis fusion protein and uses thereof
#513Dendritic Cells (DCs) Targeting for Tuberculosis (TB) Vaccine
#514Methods for producing an immune response to tuberculosis
#515INTRANASAL SPRAY-TYPE TUBERCULOSIS VACCINE USING PARAMYXOVIRUS VECTOR
#516Methods and compositions for treating autoimmune diseases
#517Antibody profiles characteristic of tuberculosis state
#518Use of BCG killed by extended freeze drying (EFD) for preventing or treating atherosclerosis
#519POLYMER PARTICLES AND USES THEREOF
#520Identification of virulence associated regions RD1 and RD5 leading to improve vaccine of BCG and
#521Microbial vaccine and vaccine vector
#522Antigen specific multi epitope-based anti-infective vaccines
#523EXPANDING THE T CELL REPERTOIRE TO INCLUDE SUBDOMINANT EPITOPES BY VACCINATION WITH ANTIGENS DELIVERED AS PROTEIN FRAGMENTS OR PEPTIDE COCKTAILS
#524RECOMBINANT MYCOBACTERIUM STRAIN EXPRESSING A MYCOBACTERIAL FAP PROTEIN UNDER THE CONTROL OF A PROMOTER ACTIVE UNDER HYPOXIA AND ITS APPLICATION FOR CANCER THERAPY
#525Methods and compositions for promoting a cell-mediated immune response
#526Compositions and methods for immunodominant antigens of
#527Compositions and methods for inducing an immune response
#528Method for the purification of protein complexes
#529Mycobacterium mutants for vaccines with improved protective efficacy
#530Tuberculosis vaccines comprising antigens expressed during the latent infection phase
#531Multivalent PCV2 immunogenic compositions and methods of producing such compositions
#532Methods for producing an immune response to tuberculosis
#533Proteins expressed by and not by BCG and their use as diagnostic reagents and vaccines
#534AUXOTROPHIC RECOMBINANT BCG STRAIN PASTEUR AND USE THEREOF IN THE CONTROL OF HUMAN INFECTIONS CAUSED BY PARASITES
#535Method of producing rough strains of bacteria and uses thereof
#536MSP nanopores and related methods
#537METHOD AND COMPOSITIONS
#538Treatment of allergic conditions using a composition containing synthetic adjuvant
#539Tuberculosis TB vaccine to prevent reactivation
#540Methylated heparin-binding hemagglutinin recombinant mycobacterial antigen, preparation method and immunogenic compositions comprising same
#541Vaccines comprising TB10.4
#542Methods for detecting a infection
#543Phospholipid drug analogs
#544Antibody Profiles Characteristic of Tuberculosis State
#545MODIFIED CATIONIC LIPOSOME ADJUVANS
#546Multivalent vaccines comprising recombinant viral vectors
#547ANTIGENIC COMPOSITIONS
#548Immunotherapeutic agent suitable for the primary prophylaxis of tuberculosis
#549Effective new drug target for the treatment of tuberculosis
#550Multivalent vaccines comprising recombinant viral vectors
#551Adjuvant combinations of liposomes and mycobacterial lipids for immunization compositions and vaccines
#552Compositions and methods for immunodominant antigens of
#553METHODS OF ENHANCING THE IMMUNOGENICITY OF MYCOBACTERIA AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUBERCULOSIS, AND FIBROSING LUNG DISEASES
#554Therapeutic calcium phosphate particles and methods of manufacture and use
#555MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
#556Compositions and methods
#557Method for purifying protein complexes
#558Tuberculosis vaccines comprising antigens expressed during the latent infection phase
#559TUBERCULOSIS RV2386C PROTEIN, COMPOSITIONS AND USES THEREOF
#560Immunogenic formulation
#561Antigens for paratuberculosis diagnosis and vaccination
#562Compositions Comprising Salmonella Porins and Uses Thereof as Adjuvants and Vaccines
#563METHODS AND MATERIALS FOR PRODUCING IMMUNE RESPONSES AGAINST POLYPEPTIDES INVOLVED IN ANTIBIOTIC RESISTANCE
#564TB VACCINE
#565vaccine
#566Cattle vaccines
#567COMPOUNDS AND METHODS FOR DIAGNOSIS AND IMMUNOTHERAPY OF TUBERCULOSIS
#568Immunogenic constructs
#569Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use
#570Recombinant BCG tuberculosis vaccine designed to elicit immune responses to mycobacterium tuberculosis in all physiological stages of infection and disease
#571ENHANCEMENT OF TRANSGENE EXPRESSION FROM VIRAL-BASED VACCINE VECTORS BY EXPRESSION OF SUPPRESSORS OF THE TYPE I INTERFERON RESPONSE
#572NOVEL COMPOSITIONS AND METHODS
#573Vaccine for the treatment of related disorders
#574Methods to increase transgene expression from bacterial-based delivery systems by co-expressing suppressors of the eukaryotic type I interferon response
#575Treatment and prevention of tuberculosis
#576VACCINE COMPOSITION CONTAINING SYNTHETIC ADJUVANT
#577Combination vaccines against sp. and methods of using the same
#578PROTEINS EXPRESSED BY MYCOBACTERIUM TUBERCULOSIS AND NOT BY BCG AND THEIR USE AS VACCINES
#579Preparation Comprising Mycobacterium Bovis BCG Killed by Extended Freeze Drying (EFD) for Preventing or Treating Rheumatoid Arthritis
#580Anti-infective agents and uses thereof
#581VACCINE
#582Polypeptide vaccine and vaccination strategy against mycobacterium
#583DIAGNOSTIC METHOD AND KIT
#584Therapeutic TB vaccine
#585VACCINE COMPOSITION CONTAINING SYNTHETIC ADJUVANT
#586Methods for producing an immune response to tuberculosis
#587MOLECULAR ADJUVANT
#588antigens
#589Immunogenic compositions against tuberculosis
#590Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
#591Synthetic glucopyranosyl lipid adjuvants
#592Novel Medicinal Formulation for Inducing an Immune Response in Patients with Chronic and Recurring Infections
#593Growth regulatable recombinant BCG compositions
#594Allelic exchange mutagenesis in Map
#595PHARMACEUTICALS COMPOSITIONS COMPRISING ACTINOMYCETE GLYCEROL ACYL DERIVATIVES ANTIGENS, THEIR PROCESS OF EXTRACTION, AND THEIR USE AGAINST TUBERCULOSIS
#596Recombinant BCG strains with enhanced ability to escape the endosome
#597Recombinant baculovirus vaccine
#598Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids
#599Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof
#600Unmarked recombinant intracellular pathogen immunogenic compositions expressing high levels of recombinant proteins